Aaron Osborne
About
In The Last Decade
Aaron Osborne
37 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 102
- Ophthalmology 1.2k
- Radiology, Nuclear Medicine and Imaging 1.1k
- Molecular Biology 300
- Physiology 89
- Immunology 83
Countries citing papers authored by Aaron Osborne
This map shows the geographic impact of Aaron Osborne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Osborne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Osborne more than expected).
Fields of papers citing papers by Aaron Osborne
This network shows the impact of papers produced by Aaron Osborne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Osborne. The network helps show where Aaron Osborne may publish in the future.
Co-authorship network of co-authors of Aaron Osborne
This figure shows the co-authorship network connecting the top 25 collaborators of Aaron Osborne. A scholar is included among the top collaborators of Aaron Osborne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron Osborne. Aaron Osborne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 10 | |
| 2 | 50 | |
| 3 | 179 | |
| 4 | 12 | |
| 5 | 30 | |
| 6 | Machine learning to predict the individual progression of AMD from imaging biomarkers | 2 |
| 7 | Defining disease endophenotypes in neovascular AMD by unsupervised machine learning of large-scale OCT data | 1 |
| 8 | 135 | |
| 9 | Effectiveness of quarterly (Q3M) versus monthly (QM) ranibizumab according to initial gains in visual acuity - an analysis of 12 month data from the EXCITE study | 2 |
| 10 | 38 | |
| 11 | 76 | |
| 12 | 4 | |
| 13 | 23 | |
| 14 | 21 | |
| 15 | 36 | |
| 16 | 22 | |
| 17 | 25 | |
| 18 | 11 | |
| 19 | 9 | |
| 20 | 57 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.